Bringing GCP to the Imaging Suite ™
MedQIA is a full service imaging CRO that specializes in cutting edge Quantitative Image Analysis for clinical trials. What sets us apart is our ability to develop and validate novel imaging biomarkers for use in global, regulated clinical trials.
Latest News
May 16, 2012 Come Visit MedQIA at ATS 2012 in San Francisco
MedQIA will be exhibiting at the American Thoracic Society International Conference May 20 – 22. Come see us at Booth #1426!… more
FibroGen Announces Promising Preliminary Data from an Open-label Phase 2 Study
FibroGen Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update
San Francisco, CA – May 3, 2012 – FibroGen, Inc., … more
April 3, 2012 New Publication by Dr. Matthew Brown, Chief Scientific Officer for MedQIA in the Journal of Nuclear Medicine Communications
Computer-aided quantitative bone scan assessment of prostate cancer treatment response
More than 90% of patients with advanced prostate cancer develop bone metastases, which can produce some of the most severe complications of the disease, including pain and spinal cord compromise. … more
March 14, 2012 Dr. Jonathan Goldin, Chief Medical Officer of MedQIA will present today at Bristol-Myers Squibb’s Day of Imaging
The Day of Imaging is designed to introduce participants to imaging technologies and specific applications in oncology, immuno-oncology, fibrosis and neuroscience. It is also a unique networking opportunity for speakers and participants alike to share knowledge about state-of-the-art imaging applications … more
All News
|
